UA117941C2 - МОДУЛЯТОРИ ROR-ГAMMA (RORγ) - Google Patents

МОДУЛЯТОРИ ROR-ГAMMA (RORγ)

Info

Publication number
UA117941C2
UA117941C2 UAA201607189A UAA201607189A UA117941C2 UA 117941 C2 UA117941 C2 UA 117941C2 UA A201607189 A UAA201607189 A UA A201607189A UA A201607189 A UAA201607189 A UA A201607189A UA 117941 C2 UA117941 C2 UA 117941C2
Authority
UA
Ukraine
Prior art keywords
alkyl
cycloalkylc
groups optionally
cycloalkyl
optionally substituted
Prior art date
Application number
UAA201607189A
Other languages
English (en)
Ukrainian (uk)
Inventor
Йосеф Марія Ґерардус Барбара Калс
Сандер Бернардус Набуурс
Original Assignee
Лід Фарма Холдінг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лід Фарма Холдінг Б.В. filed Critical Лід Фарма Холдінг Б.В.
Publication of UA117941C2 publication Critical patent/UA117941C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201607189A 2013-12-05 2014-12-03 МОДУЛЯТОРИ ROR-ГAMMA (RORγ) UA117941C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195813 2013-12-05
EP14183274 2014-09-02
PCT/EP2014/076390 WO2015082533A1 (en) 2013-12-05 2014-12-03 Ror gamma (rory) modulators

Publications (1)

Publication Number Publication Date
UA117941C2 true UA117941C2 (uk) 2018-10-25

Family

ID=52021176

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201607189A UA117941C2 (uk) 2013-12-05 2014-12-03 МОДУЛЯТОРИ ROR-ГAMMA (RORγ)

Country Status (29)

Country Link
US (1) US9738600B2 (enExample)
EP (1) EP3077372B8 (enExample)
JP (1) JP6461960B2 (enExample)
KR (1) KR102251128B1 (enExample)
CN (1) CN105980353B (enExample)
AU (1) AU2014359324B2 (enExample)
CA (1) CA2932483C (enExample)
CL (1) CL2016001364A1 (enExample)
CR (1) CR20160303A (enExample)
DK (1) DK3077372T3 (enExample)
DO (1) DOP2016000125A (enExample)
EA (1) EA030393B1 (enExample)
ES (1) ES2722409T3 (enExample)
HR (1) HRP20190483T1 (enExample)
HU (1) HUE043258T2 (enExample)
IL (1) IL246018B (enExample)
LT (1) LT3077372T (enExample)
MX (1) MX368721B (enExample)
MY (1) MY179106A (enExample)
PE (1) PE20160891A1 (enExample)
PH (1) PH12016501066A1 (enExample)
PL (1) PL3077372T3 (enExample)
PT (1) PT3077372T (enExample)
RS (1) RS58650B1 (enExample)
SI (1) SI3077372T1 (enExample)
TN (1) TN2016000224A1 (enExample)
UA (1) UA117941C2 (enExample)
WO (1) WO2015082533A1 (enExample)
ZA (1) ZA201604043B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11084784B2 (en) 2014-03-27 2021-08-10 Piramal Enterprises Limited ROR-gamma modulators and uses thereof
EA201691491A1 (ru) * 2014-04-16 2017-02-28 Гленмарк Фармасьютикалс С.А. Арильные и гетероарильные эфиры в качестве модуляторов ror-гамма
JOP20200117A1 (ar) 2014-10-30 2017-06-16 Janssen Pharmaceutica Nv كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t
KR20170075787A (ko) 2014-10-30 2017-07-03 얀센 파마슈티카 엔.브이. RORγt의 조절제로서의 아미드 치환된 티아졸
LT3212641T (lt) 2014-10-30 2019-02-11 Janssen Pharmaceutica Nv Tiazolai, kaip roryt moduliatoriai
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
DK3294713T5 (da) 2015-05-15 2021-05-31 Aurigene Discovery Tech Ltd Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
WO2016193894A1 (en) * 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) * 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) * 2015-07-10 2017-01-19 塩野義製薬株式会社 RORγt阻害作用を有する化合物およびそれらを含有する医薬組成物
TWI728017B (zh) 2015-12-15 2021-05-21 瑞典商阿斯特捷利康公司 異吲哚化合物、包含其之醫藥組成物及其用途
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為RORγT調節劑之6-胺基吡啶-3-基噻唑
WO2018011747A1 (en) * 2016-07-14 2018-01-18 Cadila Healthcare Limited Polycyclic compounds as ror-gamma modulators
TW201811760A (zh) 2016-07-14 2018-04-01 印度商卡迪拉保健有限公司 新穎的環丙基衍生物
AR110481A1 (es) * 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
WO2018116285A1 (en) * 2016-12-23 2018-06-28 Glenmark Pharmaceuticals S.A. Substituted morpholine derivatives as ror gamma modulators
JP2020524660A (ja) 2017-06-14 2020-08-20 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Ror−ガンマモジュレーターとして有用な2,3−ジヒドロイソインドール−1−カルボキサミド
JP2021529161A (ja) 2018-06-18 2021-10-28 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレーターとしてのピリジニルピラゾール
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ.ベー. RORγtのモジュレータとしてのアミド置換チアゾール
CA3103770A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
WO2019244001A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of roryt
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
JP7566889B2 (ja) * 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Il-17aモジュレーターおよびその使用
CN112759541B (zh) * 2019-10-21 2023-03-17 复旦大学 类吲哚衍生物及其用途
CN113072521B (zh) * 2020-01-06 2024-04-05 广东东阳光药业股份有限公司 RORγt抑制剂及其在药物中的应用
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
CN114075139B (zh) * 2020-08-14 2025-09-26 广东东阳光药业股份有限公司 五元杂芳环类化合物及其在药物中的应用
WO2025157313A1 (zh) * 2024-01-26 2025-07-31 上海医药集团股份有限公司 一种乙磺酰苯基乙酰胺类化合物的晶型、其制备方法及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2909189B8 (en) * 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroaryl linked quinolinyl modulators of ror-gamma-t
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
CN105121404A (zh) * 2013-03-15 2015-12-02 豪夫迈·罗氏有限公司 作为RORc调节剂的芳基磺酰胺和氨基磺酸衍生物
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators

Also Published As

Publication number Publication date
KR20160105413A (ko) 2016-09-06
CN105980353B (zh) 2019-06-14
MX368721B (es) 2019-10-14
CA2932483C (en) 2022-05-17
JP2017504576A (ja) 2017-02-09
IL246018A0 (en) 2016-08-02
CN105980353A (zh) 2016-09-28
IL246018B (en) 2020-01-30
US9738600B2 (en) 2017-08-22
AU2014359324A1 (en) 2016-07-14
RS58650B1 (sr) 2019-05-31
SI3077372T1 (sl) 2019-07-31
EA030393B1 (ru) 2018-07-31
PT3077372T (pt) 2019-03-21
BR112016012663A2 (pt) 2017-08-08
EP3077372B1 (en) 2019-02-06
TN2016000224A1 (en) 2017-10-06
EA201691173A1 (ru) 2016-11-30
ES2722409T3 (es) 2019-08-09
EP3077372B8 (en) 2019-04-10
MY179106A (en) 2020-10-28
HRP20190483T1 (hr) 2019-05-17
CR20160303A (es) 2016-11-10
NZ721511A (en) 2020-10-30
US20160304448A1 (en) 2016-10-20
CA2932483A1 (en) 2015-06-11
DOP2016000125A (es) 2016-08-31
DK3077372T3 (en) 2019-04-23
PH12016501066A1 (en) 2016-07-11
KR102251128B1 (ko) 2021-05-12
HUE043258T2 (hu) 2019-08-28
LT3077372T (lt) 2019-03-25
AU2014359324B2 (en) 2019-02-21
WO2015082533A1 (en) 2015-06-11
PE20160891A1 (es) 2016-09-24
JP6461960B2 (ja) 2019-01-30
PL3077372T3 (pl) 2019-09-30
EP3077372A1 (en) 2016-10-12
ZA201604043B (en) 2017-08-30
MX2016007275A (es) 2017-01-05
CL2016001364A1 (es) 2016-12-02

Similar Documents

Publication Publication Date Title
UA117941C2 (uk) МОДУЛЯТОРИ ROR-ГAMMA (RORγ)
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
UY37007A (es) Compuestos derivados de purinas, estimuladores de genes de interferón
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
UY37900A (es) Nuevos derivados de rapamicina
CY1120682T1 (el) Ενωσεις για την προστασια κυτταρων
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
EA201590539A1 (ru) C17-гетероарильные производные олеаноловой кислоты и способы их применения
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
NZ723198A (en) Anthelmintic compounds and compositions and methods of using thereof
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MY166151A (en) Novel thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
CY1119296T1 (el) Ενωση δικαρβοξυλικου οξεος
MX2016015467A (es) Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
MX2016009589A (es) Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes.
MX344911B (es) Compuestos de eter amido-piridilico y composiciones y su uso contra parasitos.
PH12013501856A1 (en) Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these
CO2022002022A2 (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
PH12014502066A1 (en) Triazinone compound and t-type calcium channel inhibitor
BR112017026223A2 (pt) moduladores de ror gama (rory)
WO2021007313A8 (en) Wnt activators and methods of use
AR085700A1 (es) Compuestos reguladores del crecimiento de las plantas